Regulatory milestones

Algeta ASA (OSE:ALGETA) gained NOK16 to NOK220 last week after FDA approved an NDA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Xofigo is under review in Europe.